Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pediatric Transplant Program topic
No spam. Unsubscribe anytime.
Lawmakers consider $16 million to start in‑state pediatric stem cell and bone marrow transplant program
Summary
SB228 would appropriate $16 million to establish a pediatric stem cell and bone marrow transplant program in Nevada: $7 million for infrastructure and equipment; $2.5 million for the first five transplants; and roughly $6.5 million for initial operating costs across two fiscal years. Sponsor and medical advocates said the investment would keep
Senator Julie Pizzina introduced Senate Bill 228, which would appropriate a total of $16,000,000 to establish an in‑state pediatric stem cell and bone marrow transplant program. The proposal breaks the appropriation into capital and startup funding, startup clinical costs for the initial transplants and operational support for the program’s first two years.
Sponsor testimony described the absence of an in‑state pediatric transplant program that forces families to travel out of state for life‑saving care, increasing emotional and financial burdens and interrupting continuity of care. Annette Logan Parker of Cure for the Kids testified on clinical need and economic impact. She presented a third‑party (Tripp Umbach) analysis, which the witnesses provided to the committee, estimating the state’s existing Medicaid out‑of‑state pediatric bone marrow transplant spending averages $7.1 million per year and that a one‑time $16 million investment could generate approximately $24 million in local health care revenue and $52.7 million in annual economic impact in the first fully operational year. The analysis also projected annual Medicaid savings of about $1.9 million once the program is operating.
Supporters from Intermountain Health and other hospital systems backed the bill as essential to establish local capacity, reduce family hardship, and to support a future pediatric subspecialty fellowship program. They said the funding would be used for construction and upgrades to facilities, accreditation costs through the Foundation for the Accreditation of Cellular Therapy, equipment, and to cover the high cost of the first transplants while the program achieves accreditation and payer agreements.
Committee members asked whether the program could be established and spend the funds within the bill’s required dates; witnesses acknowledged accreditation and program build‑out take time and indicated they expected initial start‑up activity and the first transplants would extend into the coming biennium. Sponsor and proponents said the appropriation is intended as a one‑time seed investment to create a sustainable program that retains care and spending in Nevada.
The hearing closed with general support from hospitals and advocacy groups. No formal committee vote occurred at the hearing; proponents said they would return with further implementation timelines and details as the bill advances.
